natgillin/translations-raw huggingface dataset:
The safety in all the performed studies covering thousands of patients is reassuring and was comparable to placebo. 
Varnost je bila v vseh raziskavah, ki so zajele na tisoče bolnikov, pomirjujoča in primerljiva s placebom.
These indicate efficacy even if modest. 
Iz obeh je razvidna učinkovitost, čeprav je skromna.
The absolute bioavailability is unknown. 
Absolutna biološka uporabnost ni znana.
The applicant nonetheless mainly referred to the two large and long-term studies by Reginster and Pavelka. 
Vlagatelj se je kljub temu v glavnem skliceval na dve veliki, dolgoročni raziskavi, ki sta ju opravila Reginster in Pavelka.
13 C 1327 Lysaker Norway 
13 C 1327 Lysaker Norveška
Since 1980 many clinical studies of glucosamine have been performed, with varying scientific relevance and quality. 
Od leta 1980 je bilo opravljenih veliko kliničnih raziskav glukozamina, ki se razlikujejo v znanstvenem pomenu in kakovosti.
1250 mg glucosamine once daily for relief of symptoms. 
1250 mg glukozamina enkrat dnevno za lajšanje simptomov.
From animal studies only insufficient data are available. 
Podatki iz študij na živalih so nepopolni.
When it comes to relative benefit and risk assessment, the influence of publication bias may be less. 
Kar se tiče relativnosti ocene razmerja med koristmi in tveganji, bo vpliv pristranskosti izhajajoče iz publikacij, verjetno manjši.
Benefit/risk assessment 
Vrednotenje koristi in tveganj
The safety profiles are, however, inferior to glucosamine. 
Vendar so varnostni profili slabši kot pri glukozaminu.
Different views on glucosamine, due to different interpretations of regulatory/legal systems have resulted in glucosamine being classified as a medicinal product in many regions of the world, including some Member States. 
Zaradi različnih pogledov na glukozamin, ki so posledica različnih interpretacij zakonskih/pravnih sistemov, je glukozamin v veliko delih sveta, med drugim nekaterih državah članicah, uvrščen med zdravila.
Overall the safety profile is favourable with mainly mild gastrointestinal symptoms reported. 
Na splošno je varnostni profil ugoden, poročali so večinoma o blagih gastrointestinalnih simptomih.
Glucosamine is considered to be an simple substance with a high solubility, and therefore, a comparative bioavailability study was not considered necessary for an approval. 
Glukozamin se šteje za preprosto spojino, ki ima veliko topnost, zato se je zdelo, da primerjalna raziskava biološke uporabnosti za odobritev ni potrebna.
Weifa AS, Hausmannsgate 6, P. O. box 9113, Grønland, 0133 Oslo, Norway This medicinal product is authorised in the Member States of the EEA under the following names: Austria 
Weifa AS, Hausmannsgate 6, P. O. box 9113, Grønland, 0133 Oslo, Norveška Zdravilo je v državah članicah EGP pridobilo dovoljenje za promet z naslednjimi imeni: Avstrija
Pack-sizes of 40, 60 or 180 tablets. 
Velikosti pakiranj: 40, 60 ali 180 tablet.
No specific studies have been performed in the elderly, but according to clinical experience dosage adjustment is not required when treating otherwise healthy, elderly patients. 
Pri starejših ljudeh niso bile opravljene posebne študije, vendar v skladu z dosedanjimi kliničnimi izkušnjami prilagajanje odmerkov pri starejših, sicer zdravih ljudeh, ni potrebno.
These two studies use authorised glucosamine-containing medicinal products, are long-term 3-years placebo-controlled studies, include an appropriate number of patients with appropriate inclusion criteria and look at relevant endpoints. 
Obe raziskavi uporabljata odobreno zdravilo, ki vsebuje glukozamin, sta dolgoročni 3 leta trajajoči, s placebom nadzorovani raziskavi, obsegata dovolj veliko število bolnikov z ustreznimi vključitvenimi kriteriji in določata pomembne končne točke.
Concurrent treatment with glucosamine may increase the absorption and serum concentration of tetracyclines, but the clinical relevance of this interaction is probably limited. 
Hkratno zdravljenje z glukozaminom lahko poveča absorpcijo in serumsko koncentracijo tetraciklinov, vendar je klinični pomen teh interakcij verjetno omejen.
Sporadic, spontaneous cases of hypercholesterolaemia have been reported, but causality has not been established. 
Poročali so o posameznih spontanih primerih hiperholesterolemije, vendar vzročnost ni bila ugotovljena.
In addition the applicant was asked to justify the proposed dose and posology, to characterise the safety profile, including a discussion of reported adverse drug reactions (ADRs), to justify the relevance of literature considering that the formulations of glucosamine sulphate (as the sodium chloride complex) used in the cited literature differ from the concerned application formulation and whether the differences in formulation will alter the efficacy and safety of the product, to elucidate the possibility of interactions with other medicinal products, and finally to show a positive risk/benefit profile of glucosamine hydrochloride in the intended indication. 
Poleg tega je bil vlagatelj naprošen, da upraviči predlagani odmerek in odmerjanja; da opiše varnostni profil, vključno z razpravo o navedenih neželenih učinkih zdravila (ADR); da upraviči ustreznost literature, saj navedena literatura opisuje formulacijo glukozamin sulfata (kot kompleks z natrijevim kloridom), ki se razlikuje od formulacije v zadevni vlogi, ter navede, ali razlike v formulaciji spremenijo učinkovitost in varnost zdravila; da razjasni možnost medsebojnega delovanja z drugimi zdravili; ter kot zadnje, da dokaže pozitivno razmerje med koristmi in tveganji za glukozamin hidroklorid za predvideno indikacijo.
Glucosamine is not indicated for the treatment of acute painful symptoms. 
Glukozamin ni indiciran za zdravljenje akutnih bolečinskih simptomov.
Glucomed United Kingdom [To be completed nationally] 
Glucomed Velika Britanija [izpolni država članica]
If no relief of symptoms is experienced after 2-3 months, continued treatment with glucosamine should be re-evaluated. 
Če olajšanje bolečine ne nastopi po 2-3 mesecih zdravljenja, je potrebno nadaljnje zdravljenje z glukozaminom ponovno ovrednotiti.
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANT, MARKETING AUTHORISATION HOLDER IN THE MEMBER STATES 
DODATEK I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE ZDRAVILA, PREDLAGATELJA, IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF GLUCOMED AND ASSOCIATED NAMES (see Annex I) 
SPLOŠNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA GLUCOMED IN Z NJIM POVEZANIH IMEN (glejte Dodatek I)
In the most recent meta-analysis from the Cochrane group in 2005, the results are positive when a glucosamine-containing medicinal product was used, positive for placebo-controlled studies in general and negative when the studies with adequate allocation concealment are retained. 
V zadnji metaanalizi Cochranove skupine leta 2005 so bili rezultati pozitivni kadar se jemljejo zdravila, ki vsebuje glukozamin, pozitivni za s placebom nadzorovane raziskave na splošno in negativni, ko so obdržali le raziskave z zadostno zaslepljenostjo načina zdravljenja.
Like all medicines, Glucomed can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Glucomed neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
The mechanism of action of glucosamine in humans is unknown. 
Mehanizem delovanja glukozamina pri ljudeh ni znan.
For both studies the results are statistically significant for the WOMAC scale (Reginster) and for WOMAC and Lequesne scale (Pavelka) at 3 years. 
V obeh raziskavah so bili rezultati po 3 letih statistično pomembni po lestvici WOMAC (Reginster) in lestvici WOMAC in Lequesne (Pavelka).
Luxembourg Glucomed Netherlands 
Luksemburg Glucomed Nizozemska Glucomed Norveška
Glucosamine is a relatively small molecule (molecular mass 179), which is easily dissolved in water and soluble in hydrophilic organic solvents. 
Glukozamin je relativno majhna molekula (molekulska masa 179), ki je dobro topna v vodi in topna v hidrofilnih organskih topilih.
Dose selection in this bibliographical application is made from experience from other related glucosamine products and the dose and posology chosen is the same as used in almost all performed studies. 
Izbira odmerka v tej bibliografski vlogi je temeljila na izkušnjah iz drugih sorodnih glukozaminskih zdravil, izbrana odmerek in način odmerjanja pa sta bila enaka kot v skoraj vseh ostalih opravljenih raziskavah.
¾ The scope of the referral was to discuss the benefit/risk of glucosamine hydrochloride in the proposed indication ¾ The Summary of Products Characteristic, labelling and package leaflet proposed by the applicant has been assessed based on the documentation submitted and the scientific discussion within the Committee. 
¾ Namen napotitvenega postopka je bil razpravljati o razmerju med koristmi in tveganji glukozamin hidroklorida za predlagano indikacijo, ¾ Povzetek glavnih značilnosti zdravila, označevanje in Navodila za uporabo, ki jih je predlagal vlagatelj, so bili ovrednoteni na podlagi predložene dokumentacije in znanstvene razprave znotraj Odbora.
Within this referral procedure, a question was raised, whether Glucomed containing glucosamine hydrochloride, was as effective as glucosamine sulphate. 
Med tem napotitvenim postopkom se je pojavilo vprašanje, ali je zdravilo Glucomed, ki vsebuje glukozamin hidroklorid, enako učinkovito kot glukozamin sulfat.
Pharmacovigilance surveillance has resulted in some reports indicating a potential interaction with warfarin, and hence a warning has been added in the SPC text. 
V okviru farmakovigilančnega spremljanja se je pojavilo nekaj poročil o potencialnem medsebojnem delovanju z varfarinom, zato je bilo v besedilo SPC dodano opozorilo.
PHARMACEUTICAL FORM AND CONTENTS 40 tablets 
FARMACEVTSKA OBLIKA IN VSEBINA 40 tablet
There is no data available on the excretion of glucosamine in human milk. 
Ni podatkov o izločanju glukozamina v humano mleko.
A report on exacerbated asthma symptoms triggered after initiation of glucosamine therapy has been described (symptoms resolved after withdrawal of glucosamine). 
Opisano je poročilo o poslabšanju simptomov astme, ki se je pojavilo po začetku zdravljenja z glukozaminom (simptomi so izginili po prenehanju jemanja glukozamina).
Glucosamine 
glukozamin
Take special care with Glucomed - if you suffer from impaired glucose tolerance. 
Bodite posebno pozorni pri uporabi zdravila Glucomed - če trpite zaradi okvarjene tolerance za glukozo.
Asthmatic patients starting on glucosamine should therefore be aware of potential worsening of symptoms. 
Bolniki z astmo, ki začenjajo z jemanjem glukozamina, se morajo zavedati možnosti poslabšanja simptomov.
A doctor must be consulted to rule out the presence of joint diseases for which other treatment should be considered. 
Pred zdravljenjem se je treba posvetovati z zdravnikom, da se izključi možnost ostalih sklepnih bolezni, ki zahtevajo drugačno zdravljenje.
Patients treated with coumarin anticoagulants should therefore be monitored closely when initiating or ending glucosamine therapy. 
Bolnike, ki se zdravijo s kumarinskimi antikoagulanti, je zato potrebno skrbno spremljati ob uvajanju in prenehanju zdravljenja z glukozaminom.
WHAT GLUCOMED IS AND WHAT IT IS USED FOR Glucomed belongs to the group of medicines called other anti-inflammatory and anti-rheumatic agents, non-steroids. 
KAJ JE ZDRAVILO GLUCOMED IN ZA KAJ GA UPORABLJAMO Glucomed spada v skupino zdravil, ki jih imenujemo druga protivnetna in protirevmatična zdravila, nesteroida zdravila.
Relief of symptoms (especially pain relief) may not be experienced until after several weeks of treatment and in some cases even longer. 
Zdravljenje lahko traja nekaj tednov, v nekaterih primerih celo dlje, preden nastopi olajšanje simptomov (še posebej olajšanje bolečine).
Do not take Glucomed - if you are allergic (hypersensitive) to glucosamine or to any of the other ingredients of Glucomed. 
Ne jemljite zdravila Glucomed - če ste alergični na (preobčutljivi za) glukozamin ali na katerokoli sestavino zdravila Glucomed.
Vollsveien 13 C, P.O. box 438, 1327 Lysaker, Norway Manufacturer: 
Vollsveien 13 C, P.O. box 438, 1327 Lysaker, Norveška Izdelovalec:
Pack-sizes of 60 or 180 tablets. 
Velikosti pakiranj: 60 ali 180 tablet.
Caution should be exercised if Glucomed has to be combined with other medicines, especially warfarin and tetracycline. 
Previdnost je potrebna pri kombinacijah zdravila Glucomed z drugimi zdravili, še posebej z varfarinom in tetraciklini.
The efficacy in symptomatic relief of pain in osteoarthritis, of the existing alternatives, NSAIDs and paracetamol, is of similar magnitude as glucosamine (e.g. ref. review by Bjordal). 
Učinkovitost simptomatskega lajšanja bolečine pri osteoartritisu je pri obstoječih alternativah (NSPVZ in paracetamolu) podobne magnitude kot pri glukozaminu (npr. Bjordalov pregled).
Animal experimental data relating to toxicity during repeated administration, reproduction toxicity, mutagenicity and carcinogenicity is lacking for glucosamine. 
Eksperimentalnih podatkov na živalih o toksičnosti pri ponavljajočih se odmerkih, vplivu na sposobnost razmnoževanja, mutagenosti in karcinogenosti glukozamina niso pridobili.
NAME OF THE MARKETING AUTHORISATION HOLDER Navamedic ASA 
IME IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Navamedic ASA
In patients with mild to moderate osteoarthritis, in addition to physical exercise, paracetamol and NSAIDs are the only existing approved medicinal drug alternatives to obtain symptomatic relief of symptoms such as pain and stiffness. 
Za bolnike z blagim do zmernim osteoartritisom so poleg telesne vadbe nesteroidna protivnetna zdravila (NSPVZ) in paracetamol edina odobrena alternativna zdravila za lajšanje simptomov, kot sta bolečina in otrdelost.
Glucosamine was mainly introduced on the world-wide market as a food-supplement but with the aim to improve symptoms in patients with osteoarthritis or joint pain or function. 
Glukozamin se je večinoma začel tržiti po vsem svetu kot prehransko dopolnilo z namenom lajšanja simptomov pri bolnikih z osteoartritisom ali bolečinami v mišicah oz. izboljšanja funkcije sklepov.
NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Navamedic ASA, Vollsveien 13 C, P. O. box 438, 1327 Lysaker, Norway 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Navamedic ASA, Vollsveien 13 C, P. O. box 438, 1327 Lysaker, Norveška
Known hypersensitivity to glucosamine or to any of the excipients. 
Znana preobčutljivost za glukozamin ali katerokoli pomožno snov.
Common (≥1/100 to <1/10): headache, tiredness, nausea, abdominal pain, indigestion, diarrhoea, constipation. 
Pogosto (≥1/100 do <1/10): glavobol, utrujenost, slabost, bolečina v trebuhu slaba prebava, driska, zaprtje.
Pharmacotherapeutic group: Other anti-inflammatory and anti-rheumatic agents, non-steroidal antiinflammatory drugs. 
Farmakoterapevtska skupina: Druga nesteroidna protivnetna in protirevmatična zdravila, nesteroidna protivnetna zdravila
Data on possible drug interactions with glucosamine is limited, but increased INR with coumarin anticoagulants (warfarin and acenocoumarol) has been reported. 
Podatki o možnem medsebojnem delovanju glukozamina in ostalih zdravil so omejeni, vendar so poročali o povečanem INR ob sočasni uporabi kumarinskih antikoagulantov (varfarin in acenokumarol).
If dizziness or drowsiness is experienced, car driving and the operating of machinery is not recommended. 
Če se pojavita vrtoglavica ali zaspanost, se vožnja avtomobila ali upravljanje s stroji odsvetujeta.
Each tablet contains 625 mg of glucosamine (as glucosamine hydrochloride) - The other ingredients are microcrystalline cellulose, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose (L-HPC) and magnesium stearate. 
Vsaka tableta vsebuje 625 mg glukozamina (v obliki glukozaminijevega klorida) - Pomožne snovi so mikrokristalna celuloza, hidroksipropilceluloza, delno substituirana hidroksipropilceluloza (L-HPC) in magnezijev stearat.
INFORMATION IN BRAILLE Glucomed 
PODATKI V BRAILLOVI PISAVI Glucomed
There is no adequate data from the use of glucosamine in pregnant women. 
Ni ustreznih podatkov o uporabi glukozamina pri nosečnicah.
Note: This SPC, labelling and package leaflet is the version that was annexed to the Commission Decision on this Article 29 referral for glucosamine hydrochloride containing medicinal products. 
Opomba: Ta Povzetek glavnih značilnosti zdravila, označevanje in navodila za uporabo so bili priloženi k odločbi Komisije v zvezi z napotitvenim postopkom, ki je bil sprožen v skladu z členom 29, za zdravila, ki vsebujejo glukozaminijevega klorida.
The Summary of Product Characteristics, labelling and package leaflet are set out in Annex III of the opinion for Glucomed and associated names (see Annex I). 
Povzetek glavnih značilnosti zdravila, označevanje in Navodila za uporabo so navedeni v Dodatku III mnenja za zdravilo Glucomed in z njim povezana imena (glejte Dodatek I).
Results from in vitro studies and in vivo studies in animals have shown that glucosamine reduces insulin secretion and induces insulin resistance, probably via glucokinase inhibition in the beta cells. 
Podatki iz in vitro ter in vivo študij na živalih kažejo, da glukozamin zavira izločanje inzulina ter povzroča odpornost na inzulin, verjetno preko zaviranja glukokinaze v beta celicah.
Due to limited documentation on potential drug interactions with glucosamine, one should generally be aware of altered response or concentration of concurrently used medicinal products. 
Zaradi omejenih podatkov o možnih interakcijah glukozamina z ostalimi zdravili se je v splošnem potrebno zavedati, da lahko pride ob hkratni uporabi drugih zdravil do spremenjenega učinka ali koncentracij.
PVC/PVDC-aluminium blisters packed in paper cartons. 
PVC/PVDC-pretisni omoti iz aluminija pakirani v papirnatih škatlah.
In this leaflet: 
- Ob upoštevanju naslednjega:
Taking Glucomed with food and drink You can take the tablets with or without food. 
Uporaba zdravila skupaj s hrano in pijačo Zdravilo lahko zaužijete skupaj s hrano ali brez nje.
Glucomed is not recommended for use in children and adolescents below the age of 18, due to lack of data on safety and efficacy. 
Zaradi pomanjkanja podatkov o varnosti in učinkovitosti uporaba zdravila Glucomed pri otrocih in mladostnikih pod 18 let ni priporočljiva.
Store below 30˚C. 
Shranjujte pri temperaturi do 30˚C.
The most common adverse reactions associated with treatment with glucosamine are nausea, abdominal pain, indigestion, constipation, and diarrhoea. 
Najpogostejši neželeni učinki, ki so povezani z zdravljenjem z glukozaminom so: slabost, abdominalna bolečina, slaba prebava, zaprtje in driska.
What Glucomed is and what it is used for Before you take Glucomed How to take Glucomed Possible side effects 
Kaj je zdravilo Glucomed in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Glucomed Kako jemati zdravilo Glucomed Možni neželeni učinki
Keep the bottle or blister package tightly closed. 
Stekleničko ali pretisni omot shranjujte tesno zaprt.
METHOD AND ROUTE(S) OF ADMINISTRATION Read the package leaflet before use. 
POSTOPEK IN POT UPORABE Pred uporabo preberite priloženo navodilo.
5 How to store Glucomed Further information 
5 Shranjevanje zdravila Glucomed Dodatne informacije
Although data are not uniformly positive, it was concluded that taken together, glucosamine, both hydrochloride and sulphate, has shown efficacy, for the symptomatic relief in patients with mild to moderate osteoarthritis of the knee. 
Čeprav vsi podatki niso enoznačno pozitivni, je bilo ob upoštevanju vseh podatkov zaključeno, da sta oba glukozamina (hidroklorid in sulfat) izkazala učinkovitost pri lajšanju simptomov pri bolnikih z blagim do zmernim osteoartritisom kolena.
Please contact your doctor for medical advice. 
Prosimo, da se v zvezi s tem posvetujete z zdravnikom.
In patients with a known risk factor for cardiovascular disease, monitoring of the blood lipid levels is recommended, since hypercholesterolemia has been observed in a few cases in patients treated with glucosamine. 
Pri bolnikih z znanim tveganjem za srčno-žilne bolezni je priporočljivo spremljanje koncentracije lipidov v krvi, ker je bila hiperholesterolemija opažena v nekaj primerih pri bolnikih, ki so se zdravili z glukozaminom.
Do not store above 30oC. 
Shranjujte pri temperaturi do 30oC.
The available information on the pharmacokinetics of glucosamine is limited. 
Podatki o farmakokinetičnih lastnostih glukozamina, ki so na voljo so omejeni.
Member State Marketing Authorisation Holder 
Država članica Imetnik dovoljenja za promet Predlagatelj
the CHMP has recommended by majority the granting of the Marketing Authorisation of Glucomed and associated names for the following indication: “relief of symptoms in mild to moderate osteoarthritis of the knee”. 
je CHMP z večino priporočil odobritev dovoljenja za promet z zdravilom Glucomed in z njim povezanih imen za naslednjo indikacijo: „lajšanje simptomov blagega do zmernega osteoartritisa kolena“.
Uncommon (≥1/1,000 to < 1/100): rash, itching, flushing. 
Občasno (≥1/1.000 do < 1/100): izpuščaj, srbenje, pordelost kože.
Abdominal pain Indigestion Diarrhoea Constipation 
Slabost Abdominalna bolečina Slaba prebava Driska
In addition, headache, tiredness, rash, itching, and flushing have been reported. 
Poročali so tudi o glavobolu, utrujenosti, izpuščaju, srbenju in pordelosti kože.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 625 mg of glucosamine (as glucosamine hydrochloride). 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Vsaka tableta vsebuje 625 mg glukozamina (v obliki glukozaminijevega klorida).
HDPE tablet container with a silica gel desiccant in paper bags. 
HDPE vsebnik tablet s sušilnim sredstvom silikagel v papirnatih vrečkah.
Low substituted hydroxypropyl cellulose (L-HPC) Magnesium stearate 
Delno substituirana hidroksipropilceluloza (L-HPC) Magnezijev stearat
Glucosamine should not be used during pregnancy. 
Glukozamina se med nosečnostjo ne sme uporabljati.
In vitro and in vivo studies have shown glucosamine stimulates the synthesis of physiological glycosaminoglycans and proteoglycans by chondrocytes and of hyaluronic acid by synoviocytes. 
In vitro ter in vivo študije so pokazale, da glukozamin preko hondrocitov stimulira sintezo fizioloških glikozaminoglikanov in proteoglikanov, preko sinoviocitov pa sintezo hialuronske kisline.
The applicant was asked to demonstrate efficacy of glucosamine in the intended indication “relief of symptoms in mild to moderate osteoarthritis of the knee”. 
Vlagatelj je bil naprošen, da dokaže učinkovitost glukozamina za predvideno indikacijo „lajšanje simptomov blagega do zmernega osteoartritisa kolena“.
Glucosamine is an endogenous substance, a normal constituent of the polysaccharide chains of cartilage matrix and synovial fluid glucosaminoglycans. 
Glukozamin je endogena snov, običajen gradnik polisaharidne verige v hrustančnem matriksu in glikozaminoglikanov v sinovialni tekočini.
The following have been reported: 
Poročali so o naslednjih neželenih učinkih:
White to light beige, oval tablet marked with “G” and a score line. 
Bela do rahlo bež, ovalna tableta označena s črko “G” in razdelilno zarezo.
If you forget to take Glucomed 
Če ste pozabili vzeti zdravilo Glucomed
- If you have a known risk factor for cardiovascular disease, since hypercholesterolemia has been observed in a few cases in patients treated with glucosamine. 
- če imate znan dejavnik tveganja za srčno-žilno bolezen, ker je bila pri nekaj bolnikih, ki so se zdravili z glukozaminom, opažena hiperholesterolemija.
MARKETING AUTHORISATION NUMBER(S) [To be completed nationally] 
ŠTEVILKA (ŠTEVILKE) DOVOLJENJA ZA PROMET [Izpolni država članica]
Relief of symptoms in mild to moderate osteoarthritis of the knee. 
Lajšanje simptomov blagega do zmernega osteoartritisa kolena.